AI might improve patient-clinician relationships, but various underlying assumptions will need to be addressed to bring these potential benefits to fruition.
AMA J Ethics. 2020;22(5):E395-400. doi:
10.1001/amajethics.2020.395.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020;22(5):E408-415. doi:
10.1001/amajethics.2020.408.
Driven by toxic, unpredictable, unregulated supply, drug overdose deaths are rampant. Policies that support the war on drugs have to change to be helpful.
AMA J Ethics. 2020;22(8):E723-728. doi:
10.1001/amajethics.2020.723.
Jonathan Alhalel, Nicolás Francone, Sharon Post, Catherine A. O’Brian, PhD, and Melissa A. Simon, MD, MPH
Underrepresentation of individuals with limited English proficiency who speak Spanish is ongoing in phase 3 biomedical clinical trials and exacerbates health inequity.
AMA J Ethics. 2022;24(4):E319-325. doi:
10.1001/amajethics.2022.319.
Wandy D. Hernandez-Gordon, CD(DONA), BDT(DONA), CLC, CCE(ACBE)
CHWs’ work underscores need for clinicians and organizations to respond to deeply entrenched, long-standing patterns of oppression in ways that draw upon lived experience.
AMA J Ethics. 2022;24(4):E333-339. doi:
10.1001/amajethics.2022.333.